Advertisement

Clinical and Experimental Medicine

, Volume 13, Issue 4, pp 297–303 | Cite as

TFF3 and survivin expressions associate with a lower survival rate in gastric cancer

  • Jia-Rong Meng
  • Hui-Zhong Tang
  • Kai-Zong Zhou
  • Wu-Hong Shen
  • He-Yi Guo
Original Article

Abstract

Trefoil factor 3 (TFF3) and survivin with functions of inhibiting apoptosis are involved in the gastric cancer by overexpression. The purpose of this study is to examine the expression of TFF3 and survivin in patients’ tissue samples with gastric cancer and analyze the relationship between the protein expression and the different clinical records. By studying the expressions of TFF3 and survivin in gastric cancer through immunohistochemical staining and examining the survival rate via Kaplan–Meier analysis for gastric cancer patients, we found that the TFF3 and survivin positive expressions have a significant relationship with the lower survival rate comparing to that of negative expressions in the analyzed patients (P < 0.05). And moreover, patients with double positive TFF3 and survivin expressions have the lowest survival rate. TFF3 or survivin positive expression correlates with the lymph node metastasis, metastasis, and TNM stages of gastric cancer. Survival analysis indicates that survival rate has a close relationship with the age, tumor histology, tumor differentiation, degree of infiltration, lymph node metastasis, distant metastasis, and TNM stages (P < 0.01). Our data suggest that TFF3 and survivin expressions play a vital role in gastric cancer development, and these two proteins are important markers for prognosis in gastric cancer. Patients with gastric cancer can increase the survival rate through an earlier diagnosis and appropriate treatment.

Keywords

Gastric cancer Immunohistochemical staining TFF3 Survivin Prognosis Survival analysis 

Notes

Acknowledgments

This research was supported by the funding (Z07020) from the Bureau of Science and Technology of Zhangzhou City, China.

Conflict of interest

None.

References

  1. 1.
    Muskett FW, May FE, Westley BR, Feeney J (2003) Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry-Us 42:15139–15147CrossRefGoogle Scholar
  2. 2.
    Katoh M (2003) Trefoil factors and human gastric cancer (review). Int J Mol Med 12:3–9PubMedGoogle Scholar
  3. 3.
    Liu D, Chinery R, Wilding J, Gullick WJ, Kmiot W, Pignatelli M (1997) Phosphorylation of γ-catenin and epidermal growth-factor receptor by intestinal trefoil factor. Lab Investig 77:557–563PubMedGoogle Scholar
  4. 4.
    Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M (1998) Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci 95:3122–3127PubMedCrossRefGoogle Scholar
  5. 5.
    Emami S, LeFloch N, Bruynell E, Thim L, May F, Westley B, Rio MC, Mareel M, Gespach C (2001) Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J 15:351–361PubMedCrossRefGoogle Scholar
  6. 6.
    Taupin DR, Kinoshita K, Podolsky DK (2000) Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci 97:799–804PubMedCrossRefGoogle Scholar
  7. 7.
    Chen YH, Lu Y, DePlaen IG, Wang LY, Tan XD (2000) Transcription factor NF-kB signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. Biochem Biophys Res Commun 274:576–582PubMedCrossRefGoogle Scholar
  8. 8.
    Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, Ng EK, Chung SC, Malfertheiner P, Sung JJ (2002) Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 197:582–588PubMedCrossRefGoogle Scholar
  9. 9.
    Yamachika T, Werther JL, Bodian C, Babyatsky M, Tatematsu M, Yamamura Y, Chen A, Itzkowitz S (2002) Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res 8:1092–1099PubMedGoogle Scholar
  10. 10.
    Ahmed AR, Griffiths AB, Tilby MT, Westley BR, May FE (2012) TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol 180:904–916PubMedCrossRefGoogle Scholar
  11. 11.
    Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRefGoogle Scholar
  12. 12.
    Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315–5320PubMedGoogle Scholar
  13. 13.
    Anti-Cancer AoC (1999) Diagnosis rules for new common malignant tumors. Peking Union Medicai College Press, BeijingGoogle Scholar
  14. 14.
    Tang ZH, Chen HS, Zou ZK, Cai SB, Su HY, Shen HW, We WQ, Lin L, Wang YH (2008) Trefoil factor 4 and CD147 expression in carninogenesis of gastric mucosa and their correlation with angiogenesis. World Chin J Digestol 16:3631–3636Google Scholar
  15. 15.
    Kirikoshi H, Katoh M (2002) Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol 21:655–659PubMedGoogle Scholar
  16. 16.
    Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FE, Gao J, Meitner PA, Tavares R, Resnick MB (2008) Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res 14:4161–4167PubMedCrossRefGoogle Scholar
  17. 17.
    Rodrigues S, Van Aken E, Van Boxciaer S et al (2003) Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003(17):7–16CrossRefGoogle Scholar
  18. 18.
    Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, Kubota H, Nagasue N (2005) Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 11:6472–6478PubMedCrossRefGoogle Scholar
  19. 19.
    Guleng B, Han J, Yang JQ, Huang QW, Huang JK, Yang XN, Liu JJ, Ren JL (2012) TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Mol Biol Rep 39:4127–4134PubMedCrossRefGoogle Scholar
  20. 20.
    Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P, Sung JJ (2002) Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 87:91–97PubMedCrossRefGoogle Scholar
  21. 21.
    Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH, Kim HS, Choi SK, Rew JS, Park CS, Kim SJ (2006) Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol 18:957–963PubMedCrossRefGoogle Scholar
  22. 22.
    Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC (2003) Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci 48:266–271PubMedCrossRefGoogle Scholar
  23. 23.
    Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808–1812PubMedGoogle Scholar
  24. 24.
    Da CL, Xin Y, Zhao J, Luo XD (2009) Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 15:4055PubMedCrossRefGoogle Scholar
  25. 25.
    Bertazza L, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R, Nitti D (2009) Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med 7:111PubMedCrossRefGoogle Scholar
  26. 26.
    Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC (2011) Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 10:35PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jia-Rong Meng
    • 1
  • Hui-Zhong Tang
    • 2
  • Kai-Zong Zhou
    • 3
  • Wu-Hong Shen
    • 3
  • He-Yi Guo
    • 1
  1. 1.Department of PathologyThe NO. 175 Hospital of P.L.A.ZhangzhouChina
  2. 2.Zhangzhou Health Vocation CollegeZhangzhouChina
  3. 3.Department of PathologyZhangzhou HospitalZhangzhouChina

Personalised recommendations